Targeting NAMPT, which is selectively activated by oncogenic kinases to which malignant cells become “addicted,” may represent a novel therapeutic approach to cancer, either as an alternative or, more likely, as a complementary strategy to direct inhibition of the kinase enzymatic domain. This evidence concerns the gene NAMPT and cancer.